AGP Picks
View all

Vaxchora market projected to expand as cholera risk and travel demand rise

9 hours ago
Vaxchora market projected to expand as cholera risk and travel demand rise
By AI, Created 14:30 UTC, Nov 19, 2026, AGP -

The global Vaxchora market is set for faster growth through 2035, driven by rising cholera cases, more international travel to endemic regions, and wider use of single-dose oral vaccines. North America held the largest market share in 2025, according to The Business Research Company.

Why it matters: - The Vaxchora market is growing as public health agencies, travel clinics, and travelers look for faster protection against cholera. - Rising cholera incidence, outbreak preparedness, and broader travel medicine coverage are increasing demand for preventive vaccination. - The trend matters for travelers to cholera-endemic regions and for emergency response efforts where quick immunization is critical.

What happened: - The Business Research Company released its Vaxchora Market Global Market Report 2026, covering market size, trends, and forecasts through 2035. - The report says the global Vaxchora market is entering a period of rapid growth. - North America held the largest share of the Vaxchora market in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

The details: - Vaxchora is an oral vaccine designed to prevent cholera caused by Vibrio cholerae. - The vaccine is authorized for people age 2 and older traveling to regions where cholera is common. - The vaccine is specifically recommended for adults ages 18 to 64 who plan to visit cholera-prone areas. - Vaxchora is given as a single-dose liquid, ideally 10 days before possible exposure. - The market expanded in recent years because of more travel to cholera-endemic zones, stronger cholera outbreak preparedness, more travel medicine clinics, oral vaccine approvals, and better distribution networks. - Future growth is expected from more investment in global disease prevention, higher demand for single-dose vaccines, broader travel health services, stronger focus on outbreak prevention, and greater use in humanitarian and emergency response settings. - Key trends include more demand for travel-related immunizations, better awareness of cholera prevention, wider acceptance of oral vaccines, expanded travel immunization programs, and faster compliance with vaccination protocols. - One major growth driver is the increase in cholera cases worldwide. - Cholera causes severe diarrhea and dehydration and is often linked to contaminated food or water. - Poor sanitation, limited access to clean water, climate change, and more population movement to endemic regions are helping drive higher case counts. - Vaxchora stimulates the immune response against Vibrio cholerae serogroup O1. - In August 2025, the UK Health Security Agency reported eight confirmed cholera cases in England, Wales, and Northern Ireland between January and June 2025, compared with one case in the same period in 2024. - The report also points to rapid immunization needs and demand for convenient single-dose oral vaccines as key market supports. - The Business Research Company added market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables to its 2026 report set. - The company also added key technologies and future trend analysis. - A free sample report is available here. - The full report is available here.

Between the lines: - The report suggests Vaxchora is benefiting from a broader shift toward preventive travel health and outbreak readiness rather than from cholera risk alone. - The emphasis on single-dose and oral vaccination points to demand for products that are easier to deploy in clinics, travel settings, and emergency campaigns. - North America’s lead suggests established travel medicine infrastructure remains an important commercial advantage.

What's next: - The market is expected to keep expanding through 2035 as travel volumes, outbreak concerns, and vaccine adoption patterns evolve. - Broader uptake in travel health programs and humanitarian response could add further demand if cholera risks remain elevated. - More regional differences in regulation and healthcare access will likely shape adoption across the markets covered in the report.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Technology News UK

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Technology News UK

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.